Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies Source: International Congress 2014 – Asthma and COPD management Year: 2014
Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies Source: Eur Respir J, 58 (3) 2004233; 10.1183/13993003.04233-2020 Year: 2021
Phase three studies of biologics for severe asthma: could do better? Source: Eur Respir J, 50 (3) 1701108; 10.1183/13993003.01108-2017 Year: 2017
Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Sex differences in recognition of asthma in children: ISAAC Phase III Source: Eur Respir J 2005; 26: Suppl. 49, 379s Year: 2005
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Multicenter study on the variability of the sleep stage scoring algorithm ARTISANA compared to human experts – Part II: validation phase Source: Eur Respir J 2005; 26: Suppl. 49, 114s Year: 2005
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Latent classes of adults with persistent asthma: data from the multicentre INSPIRERS studies Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Is GOLD stage 0 a good predictor of the development of COPD? Preliminary results from the ECRHS II Source: Eur Respir J 2005; 26: Suppl. 49, 434s Year: 2005
Risankizumab in severe asthma: A Phase IIa, placebo-controlled study Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020
Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021